Brief: U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

Pluri

25/04/2018 12:06

April 25 (Reuters) - Pluristem Therapeutics Inc  PSTI.O :
    * U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT
OF
MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY
    * PLURISTEM THERAPEUTICS INC - IN DISCUSSIONS WITH SEVERAL
EU
COUNTRIES TO APPROVE STUDY IN EUROPE
    * PLURISTEM THERAPEUTICS INC - EXPECTS TO BEGIN PATIENT
ENROLLMENT
IN BOTH EUROPE AND U.S. DURING 2018

Source text for Eikon:  ID:nGNXspqnQ 
Further company coverage:  PSTI.O 

 (Reuters.Briefs@thomsonreuters.com)